Search Results for “Janssen” – Page 9 – media

NIH accelerates the development of new cancer immunotherapy strategies for more patients

The National Institutes of Health(NIH) and 11 leading biopharmaceutical companies have launched the Partnership for Accelerating Cancer Therapies (PACT), a five-year public-private research collaboration totaling $215 million as part of the Cancer Moonshot.
- Source: nih.gov
- 551
- October 16, 2017
Market Views NIH PACT
J&J lines up its 4-in-1 HIV pill for FDA behind rivals from Gilead, GSK

A couple of months after posting positive late-stage data for its quadruplet-in-one-pill for quelling HIV, J&J says it’s filed a marketing application with the FDA ahead of a planned marketing campaign.
- Source: Endpts
- 553
- September 27, 2017
FDA Gilead GSK HIV J&J Market Views
Pfizer sues Johnson & Johnson, alleging anticompetitive practices to maintain a drug monopoly

A legal brawl between two of the world’s largest drug companies could shape the future of a nascent market of copycat drugs that are intended to bring down the cost of the most advanced and expensive medicines.
- Source: Washingtonpost
- 702
- September 22, 2017
biosimilar Johnson & Johnson Pfizer rheumatoid arthritis
J&J scraps a multibillion-dollar hepatitis C program after rivals divvy up the market

After committing billions of dollars to a new hepatitis C cocktail that had the potential to compete with the already deeply entrenched rivals on the market, J&J is calling it quits.
- Source: endpts
- 465
- September 12, 2017
hepatitis Market Views
Biotronik’s tiny, MRI-safe CRT pacemaker secures FDA approval

Biotronik has secured approval from the US Food and Drug Admini(FDA) for its Edora HF-T QP, a MR conditional quadripolar (QP) cardiac resynchronization therapy pacemaker (CRT-P).
- Source: medicaldevices
- 539
- August 23, 2017
cardiac Company Insight New Approvals QP
ViiV’s long-acting two-drug HIV regimen hits targets

A long-acting, two-drug HIV regimen being co-developed by ViiV Healthcare and Janssen Sciences Ireland UC has shown comparable viral suppression rates to a three-drug regimen in a Phase II trial, indicating its potential to reduce the dosing burden for patients and thus improve treatment adherence. The LATTE-2 study assessed long-acting, injectable formulations of cabotegravir (ViiV) and rilpivirine (Janssen, branded Edurant), given every four or eight weeks to patients with HIV-1 infection who had already achieved viral suppression with a daily three-drug oral regimen of cabotegravir plus two nucleoside reverse transcriptase inhibitors (NRTIs). Following 96 weeks of maintenance treatment, viral suppression rates for the two-drug regimen dosed every eight weeks (94 percent) or every four weeks (87 percent) were comparable to the rate observed in patients continuing with a three-drug oral regimen (84 percent). In the study, data from which were published in The Lancet and presented at the annual conference ...
- Source: Medicaldevice-network
- 512
- July 27, 2017
Clinical Trials formulation HIV Researches

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.